Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6085
Source ID: NCT01720719
Associated Drug: Atorvastatin
Title: Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Fatty Liver|Dyslipidemias|Diabetes Mellitus
Interventions: DRUG: atorvastatin|DRUG: Vitamin E
Outcome Measures: Primary: Liver fat content(%), MRS (magnetic resonance spectroscopy analysis): liver fat content (%)., 24 weeks | Secondary: Abdominal visceral fat area(cm2), MRI (magnetic resonance imaging): abdominal visceral fat area (cm2), 24 weeks|Abdominal subcutaneous fat area(cm2), MRI(Magnetic Resonance Imaging):abdominal subcutaneous fat content (cm2), 24 weeks|Lipid profiles, lipid profiles (total cholesterol, HDL-C, LDL-C, very low density lipoprotein and free fatty acids), 24 weeks|Liver enzymes, liver enzymes (Alanine aminotransferase(ALT), Aspartate aminotransferase(AST), Gamma-glutamyl transferase(GGT)), 24 weeks|Glucose metabolism, fasting plasma glucose(FPG), postprandial plasma glucose(PPG), HbA1c, fasting C-peptide and 2-hour postprandial C-peptide, 24 weeks|Body weight, Body weight, 24 weeks|Anthropometric test, waist and hip circumferences, 24 weeks|Muscle enzymes, MM isoenzyme of creatine kinase(CK-MM), MB isoenzyme of creatine kinase(CK-MB), 24 weeks
Sponsor/Collaborators: Sponsor: Xin Gao | Collaborators: Pfizer
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 120
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2013-05
Completion Date: 2016-12
Results First Posted:
Last Update Posted: 2016-02-03
Locations: Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, 200032, China
URL: https://clinicaltrials.gov/show/NCT01720719